<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121845</url>
  </required_header>
  <id_info>
    <org_study_id>CrossRoad</org_study_id>
    <nct_id>NCT04121845</nct_id>
  </id_info>
  <brief_title>CoROnary SinuS Reducer implantatiOn for ischemiA reDuction</brief_title>
  <acronym>CrossRoad</acronym>
  <official_title>The Influence of Coronary Sinus Reducer Implantation on Exertional Capacity, Extent of Myocardial Ischemia and hrECG Markers of Arrhythmogenicity in Patients With Refractory Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory angina pectoris have low quality of life and reduced exertional
      capacity. Studies have shown that the coronary sinus reducer (CSR) implantation improves the
      quality of life. However, to date there are no firm objective data on improvement of
      exertional capacity. Studies have shown a large influence of placebo effect after
      interventional procedures, which is even more pronounced than in medically treated patients.
      As angina pectoris presents entirely subjective perception of chest discomfort, its
      improvement may be influenced by this effect in up to 30 %. The investigators will study
      weather the CSR implantation improves aerobic exertional capacity in comparison to optimal
      medical therapy alone. Further, the investigators will explore the extent of myocardial
      reversible ischemia reduction and possible influence on hrECG markers of left ventricular
      arrhythmogenicity. 40 patients with refractory angina CCS class (Canadian cardiovascular
      society) II-IV and confirmed reversible ischemia will be included. Patients will be
      randomized into two groups. The first group will undergo CSR implantation procedure. The
      second group will present a sham control group with placebo procedure. At inclusion and after
      6 months the investigators will perform cardiopulmonary exercise test (CPET), single photon
      emission tomography for detection of reversible ischemia (SPECT), high resolution ECG
      (hrECG), echocardiography and asses the subjective burden of angina according to CCS score
      and the quality of life according to the Seattle angina Questionnaire (SAQ).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Punction of the right internal jugular vein and CSR implantation procedure simulation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of CSR versus placebo procedure on exertional capacity measured by maximal oxygen consumption (VO2) during cardio-pulmonary exercise testing.</measure>
    <time_frame>6 months</time_frame>
    <description>Maximal oxygen consumption on cycle spiroergometry using the same ramp exercise protocol during the same part of the day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of CSR versus placebo procedure on exercise duration time during cardio-pulmonary exercise testing.</measure>
    <time_frame>6 months</time_frame>
    <description>Exercise duration time on cycle spiroergometry using the same continuous exercise protocol during the same part of the day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (dynamic scintigraphy).</measure>
    <time_frame>6 months</time_frame>
    <description>Dynamic myocardial scintigraphy with the use of a 4 segment model of the left ventricle for calculation of absolute regional perfusion (ml/g/min) during rest and during pharmacologic stress. Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (static scintigraphy).</measure>
    <time_frame>6 months</time_frame>
    <description>Static myocardial scintigraphy with the use of a 17 segment model for the relative calculation of regional perfusion during rest and pharmacologic stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RR interval variability as assessed by hrECG.</measure>
    <time_frame>6 months</time_frame>
    <description>5 min recording of hrECG (1000 Hz) for the calculation of RR interval variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in late potentials as assessed by hrECG.</measure>
    <time_frame>6 months</time_frame>
    <description>5 min recording of hrECG (1000 Hz) for the calculation of late potentials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QT variability as assessed by hrECG.</measure>
    <time_frame>6 months</time_frame>
    <description>5 min recording of hrECG (1000 Hz) for determination of QT variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Canadian Cardiovascular Society angina pectoris class (CCS).</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Change in CCS class I-IV. Acco</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of CSR versus placebo procedure on quality of life according to Seattle angina questionnaire (SAQ).</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Change in each of the five categories: Physical Limitation Scale (range 1-100), Anginal Stability Scale (range 1-100), Anginal Frequency Scale (range 1-100), Treatment Satisfaction Scale (range 1-100), Disease Perception Scale (range 1-100). Higher values in scale represent better outcome. Subscales are not combined.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Influence of CSR implantation on echocardiographically assessed left ventricular elastance.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Influence of CSR implantation on diastolic strain.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary sinus reducer implantation through right internal jugular vein.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary Sinus Reducer device</intervention_name>
    <description>Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.</description>
    <arm_group_label>Sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  angina pectoris CCS class II-IV

          -  receiving optimal medical therapy for at least one month

          -  confirmed reversible myocardial ischemia in left anterior descending coronary artery
             (LAD) and/or left circumflex coronary artery (LCX) territory by SPECT

          -  not candidate for percutaneous coronary intervention (PCI) or coronary artery bypass
             grafting (CABG)

        Exclusion Criteria:

          -  recent non stable angina pectoris (within 1 months)

          -  recent acute coronary syndrome (within 3 months)

          -  recent successful PCI and/or CABG (within 6 months)

          -  decompensated heart failure and/or recent (within 3 months) hospitalization due to
             heart failure

          -  severe heart valve(s) disease

          -  advanced chronic obstructive pulmonary disease (COPD) or poorly managed asthma

          -  peripheral arterial disease, musculoskeletal disorder or central nervous system
             disease which preclude exercise testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matjaž Bunc, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Žižek, Assoc. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MIha Mrak, MD</last_name>
    <phone>0038615223125</phone>
    <email>miha.mrak@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Žižek, Assoc. Prof.</last_name>
    <phone>0038615221152</phone>
    <email>david.zizek@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miha Mrak, MD</last_name>
      <phone>0038615223125</phone>
      <email>miha.mrak@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>David Žižek, Assoc. Prof.</last_name>
      <phone>0038615221152</phone>
      <email>david.zizek@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Matjaž Bunc, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miha Mrak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Žižek, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nejc Pavšič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J. 2002 Mar;23(5):355-70. Review.</citation>
    <PMID>11846493</PMID>
  </reference>
  <reference>
    <citation>Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF, Bart BA, Olson RE, Boisjolie CR, Harvey KL, Arndt TL, Traverse JH. Long-term survival in patients with refractory angina. Eur Heart J. 2013 Sep;34(34):2683-8. doi: 10.1093/eurheartj/eht165. Epub 2013 May 12.</citation>
    <PMID>23671156</PMID>
  </reference>
  <reference>
    <citation>Giannini F, Aurelio A, Jabbour RJ, Ferri L, Colombo A, Latib A. The coronary sinus reducer: clinical evidence and technical aspects. Expert Rev Cardiovasc Ther. 2017 Jan;15(1):47-58. Review.</citation>
    <PMID>27935738</PMID>
  </reference>
  <reference>
    <citation>Konigstein M, Verheye S, Jolicœur EM, Banai S. Narrowing of the Coronary Sinus: A Device-Based Therapy for Persistent Angina Pectoris. Cardiol Rev. 2016 Sep-Oct;24(5):238-43. doi: 10.1097/CRD.0000000000000101. Review.</citation>
    <PMID>26886464</PMID>
  </reference>
  <reference>
    <citation>Verheye S, Jolicœur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015 Feb 5;372(6):519-27. doi: 10.1056/NEJMoa1402556.</citation>
    <PMID>25651246</PMID>
  </reference>
  <reference>
    <citation>Konigstein M, Meyten N, Verheye S, Schwartz M, Banai S. Transcatheter treatment for refractory angina with the Coronary Sinus Reducer. EuroIntervention. 2014 Feb;9(10):1158-64. doi: 10.4244/EIJV9I10A196.</citation>
    <PMID>24561732</PMID>
  </reference>
  <reference>
    <citation>Abawi M, Nijhoff F, Stella PR, Voskuil M, Benedetto D, Doevendans PA, Agostoni P. Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience. Neth Heart J. 2016 Sep;24(9):544-51. doi: 10.1007/s12471-016-0862-2.</citation>
    <PMID>27299456</PMID>
  </reference>
  <reference>
    <citation>Banai S, Ben Muvhar S, Parikh KH, Medina A, Sievert H, Seth A, Tsehori J, Paz Y, Sheinfeld A, Keren G. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol. 2007 May 1;49(17):1783-9.</citation>
    <PMID>17466229</PMID>
  </reference>
  <reference>
    <citation>Myers J, Froelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation. 1990 Nov;82(5):1839-46. Review.</citation>
    <PMID>2225380</PMID>
  </reference>
  <reference>
    <citation>Kralios AC, Nappi JM, Tsagaris TJ, Kralios FA, Kuida H. Paradoxical increase of ventricular fibrillation threshold in response to coronary sinus obstruction. Am Heart J. 1988 Feb;115(2):334-40.</citation>
    <PMID>3341168</PMID>
  </reference>
  <reference>
    <citation>Kralios AC, Anderson FL, Kralios FA. Protective effect of coronary sinus obstruction from primary ischemia-induced ventricular fibrillation in the dog. Am Heart J. 1993 Apr;125(4):987-95.</citation>
    <PMID>8465771</PMID>
  </reference>
  <reference>
    <citation>De Maria GL, Kassimis G, Raina T, Banning AP. Reconsidering the back door approach by targeting the coronary sinus in ischaemic heart disease. Heart. 2016 Aug 15;102(16):1263-9. doi: 10.1136/heartjnl-2016-309642. Epub 2016 Jun 10. Review.</citation>
    <PMID>27288281</PMID>
  </reference>
  <reference>
    <citation>Baldetti L, Colombo A, Banai S, Latib A, Esposito A, Palmisano A, Giannini F. Coronary sinus Reducer non-responders: insights and perspectives. EuroIntervention. 2018 Feb 20;13(14):1667-1669. doi: 10.4244/EIJ-D-17-00626.</citation>
    <PMID>29086709</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Matjaž Bunc</investigator_full_name>
    <investigator_title>Head of catheterization laboratory</investigator_title>
  </responsible_party>
  <keyword>angina pectoris</keyword>
  <keyword>coronary sinus reducer</keyword>
  <keyword>quality of life</keyword>
  <keyword>reversible ischemia</keyword>
  <keyword>exercise testing</keyword>
  <keyword>oxygen consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication All IPD on special request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After study completion and results publication. Not limited.</ipd_time_frame>
    <ipd_access_criteria>All IPD that underlie results in a publication on editor/researcher request. All IPD on special request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

